title: Managing advanced prostate cancer with Viadur (leuprolide acetate implant).
abstract: Viadur (leuprolide acetate implant), providing a sustained release of drug over a 12-month duration, decreases serum testosterone in advanced prostate cancer patients, providing long-term, palliative medical hormonal therapy. Clinical experience suggests Viadur implants are safe, effective, and generally well tolerated. The continuous drug delivery provided by Viadur ensures compliance. The Viadur implants was designed to be maintenance-free, thereby allowing nurses and other health professionals to focus on other patient needs, such as followup visits and diagnostic tests. Viadur is one aspect of a comprehensive approach to patient management, which also includes regular followup for prostate-specific antigen testing, digital rectal examination, and other tests throughout the 1-year therapy.
authors: Department of Defense Center for Prostate Disease Research, Uniformed Services University, Rockville, MD, USA.
authors: J W
authors: JW
authors: Moul
authors: K
authors: K
authors: Civitelli
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D004343:Drug Implants; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000451:nursing
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004343:Drug Implants; D016729:Leuprolide